Sökning: onr:"swepub:oai:DiVA.org:uu-304522" >
Cost-effectiveness ...
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
-
- Padula, William V. (författare)
- Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA.
-
- Larson, Richard A. (författare)
- Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.
-
- Dusetzina, Stacie B. (författare)
- Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.;Univ N Carolina, Gillings Sch Global Publ Hlth, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.;Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.
-
visa fler...
-
- Apperley, Jane F. (författare)
- Imperial Coll, Hammersmith Hosp, Dept Haematol, London, England.
-
- Hehlmann, Rudiger (författare)
- Heidelberg Univ, Dept Med, Mannheim, Germany.
-
- Baccarani, Michele (författare)
- S Orsola Malpighi Univ Hosp, Dept Haematol & Oncol, Bologna, Italy.
-
- Eigendorff, Ekkehard (författare)
- Univ Hosp, Dept Haematol & Oncol, Jena, Germany.
-
- Guilhot, Joelle (författare)
- CHU Poitiers, INSERM, CIC 1402, Poitiers, France.
-
- Guilhot, Francois (författare)
- CHU Poitiers, INSERM, CIC 1402, Poitiers, France.
-
- Mahon, Francois-Xavier (författare)
- Univ Victor Segalen, Lab Hematol, Pessac, France.
-
- Martinelli, Giovanni (författare)
- Univ Bologna, Dept Hematol, L & A Seragnoli, Bologna, Italy.
-
- Mayer, Jiri (författare)
- Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.
-
- Müller, Martin C. (författare)
- Heidelberg Univ, Dept Hematol & Oncol, Mannheim, Germany.
-
- Niederwieser, Dietger (författare)
- Univ Hosp Leipzig, Dept Hematol & Oncol, Leipzig, Germany.
-
- Saussele, Susanne (författare)
- Heidelberg Univ, Dept Med, Mannheim, Germany.
-
- Schiffer, Charles A. (författare)
- Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
-
- Silver, Richard T. (författare)
- Weill Cornell Med Ctr, Dept Med, New York, NY 10065 USA.
-
- Simonsson, Bengt (författare)
- Uppsala universitet,Hematologi
-
- Conti, Rena M. (författare)
- Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.;Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
-
visa färre...
-
Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. (creator_code:org_t)
- 2016-03-04
- 2016
- Engelska.
-
Ingår i: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 0027-8874 .- 1460-2105. ; 108:7
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://academic.oup...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib's price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in these patients and then switching to the other tyrosine-kinase inhibitors (TKIs), dasatinib or nilotinib, because of intolerance or lack of effectiveness ("imatinib-first") would be cost-effective compared with the current standard of care: "physicians' choice" of initiating treatment with any one of the three TKIs. Methods: We constructed Markov models to compare the five-year cost-effectiveness of imatinib-first vs physician's choice from a US commercial payer perspective, assuming 3% annual discounting ($US 2013). The models' clinical endpoint was five-year overall survival taken from a systematic review of clinical trial results. Per-person spending on incident CML-CP treatment overall care components was estimated using Truven's MarketScan claims data. The main outcome of the models was cost per quality-adjusted life-year (QALY). We interpreted outcomes based on a willingness-to-pay threshold of $100 000/QALY. A panel of European LeukemiaNet experts oversaw the study's conduct. Results: Both strategies met the threshold. Imatinib-first ($277 401, 3.87 QALYs) offered patients a 0.10 decrement in QALYs at a savings of $88 343 over five years to payers compared with physician's choice ($365 744, 3.97 QALYs). The imatinibfirst incremental cost-effectiveness ratio was approximately $883 730/QALY. The results were robust to multiple sensitivity analyses. Conclusion: When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment strategy for CML-CP.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Padula, William ...
-
Larson, Richard ...
-
Dusetzina, Staci ...
-
Apperley, Jane F ...
-
Hehlmann, Rudige ...
-
Baccarani, Miche ...
-
visa fler...
-
Eigendorff, Ekke ...
-
Guilhot, Joelle
-
Guilhot, Francoi ...
-
Mahon, Francois- ...
-
Martinelli, Giov ...
-
Mayer, Jiri
-
Müller, Martin C ...
-
Niederwieser, Di ...
-
Saussele, Susann ...
-
Schiffer, Charle ...
-
Silver, Richard ...
-
Simonsson, Bengt
-
Conti, Rena M.
-
visa färre...
- Artiklar i publikationen
-
Journal of the N ...
- Av lärosätet
-
Uppsala universitet